These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 22641380)

  • 1. Engineering nano- and microparticles to tune immunity.
    Moon JJ; Huang B; Irvine DJ
    Adv Mater; 2012 Jul; 24(28):3724-46. PubMed ID: 22641380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering the immune system with particles, step-by-step.
    De Geest BG
    Mol Immunol; 2018 Jun; 98():25-27. PubMed ID: 29526503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomaterial Strategies for Immunomodulation.
    Hotaling NA; Tang L; Irvine DJ; Babensee JE
    Annu Rev Biomed Eng; 2015; 17():317-49. PubMed ID: 26421896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
    Klippstein R; Pozo D
    Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8
    Darling R; Senapati S; Christiansen J; Liu L; Ramer-Tait AE; Narasimhan B; Wannemuehler M
    Int J Nanomedicine; 2020; 15():6579-6592. PubMed ID: 32982219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical models and technologies to advance nanovaccine development.
    Peres C; Matos AI; Moura LIF; Acúrcio RC; Carreira B; Pozzi S; Vaskovich-Koubi D; Kleiner R; Satchi-Fainaro R; Florindo HF
    Adv Drug Deliv Rev; 2021 May; 172():148-182. PubMed ID: 33711401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gold nanoparticle mediated cancer immunotherapy.
    Almeida JP; Figueroa ER; Drezek RA
    Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
    Amoozgar Z; Goldberg MS
    Adv Drug Deliv Rev; 2015 Aug; 91():38-51. PubMed ID: 25280471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches.
    Davodabadi F; Sarhadi M; Arabpour J; Sargazi S; Rahdar A; Díez-Pascual AM
    J Control Release; 2022 Sep; 349():844-875. PubMed ID: 35908621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 13. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
    Li S; Bennett ZT; Sumer BD; Gao J
    Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional nanoparticles for cancer immunotherapy.
    Saleh T; Shojaosadati SA
    Hum Vaccin Immunother; 2016 Jul; 12(7):1863-75. PubMed ID: 26901287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of nanoparticle vaccines as a treatment for cancer.
    Urbanavicius D; Alvarez T; Such GK; Johnston APR; Mintern JD
    Mol Immunol; 2018 Jun; 98():2-7. PubMed ID: 29395251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
    Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
    Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
    Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
    Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
    Nguyen TL; Choi Y; Kim J
    Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
    Han HD; Byeon Y; Jang JH; Jeon HN; Kim GH; Kim MG; Pack CG; Kang TH; Jung ID; Lim YT; Lee YJ; Lee JW; Shin BC; Ahn HJ; Sood AK; Park YM
    Sci Rep; 2016 Dec; 6():38348. PubMed ID: 27910914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.